Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + VAH in Intermediate- to High-risk Fit AML Patients
NCT07643636Phase 2Not yet recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Dongguan People's Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07643636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643636.